The effect of istradefylline for Parkinson’s disease: A meta-analysis

[1]  K. Hirata,et al.  Istradefylline improves daytime sleepiness in patients with Parkinson's disease: An open-label, 3-month study , 2017, Journal of the Neurological Sciences.

[2]  David Eidelberg,et al.  Parkinson's disease‐related network topographies characterized with resting state functional MRI , 2017, Human brain mapping.

[3]  Chris C. Tang,et al.  Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases , 2016, Neurology.

[4]  N. Shinohara,et al.  Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson's disease , 2016, International journal of urology : official journal of the Japanese Urological Association.

[5]  R. Kaji,et al.  The difference of apparent diffusion coefficient in the middle cerebellar peduncle among parkinsonian syndromes: Evidence from a meta-analysis , 2016, Journal of the Neurological Sciences.

[6]  Y. Mizuno,et al.  A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease , 2015, Clinical neuropharmacology.

[7]  T. J. Moore,et al.  Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. , 2014, JAMA internal medicine.

[8]  R. Kaji,et al.  Reduced alpha‐synuclein in cerebrospinal fluid in synucleinopathies: Evidence from a meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[9]  H. Reichmann,et al.  Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials , 2014, European journal of neurology.

[10]  R. Kaji,et al.  Which target is best for patients with Parkinson's disease? A meta-analysis of pallidal and subthalamic stimulation , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  Y. Mizuno,et al.  Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[12]  C. Tanner,et al.  Caffeine consumption and risk of dyskinesia in CALM‐PD , 2013, Movement disorders : official journal of the Movement Disorder Society.

[13]  Hongquan Wang,et al.  Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis , 2013, Journal of the Neurological Sciences.

[14]  M. Schwarzschild,et al.  Adenosine A2A receptor gene disruption protects in an α‐synuclein model of Parkinson's disease , 2012, Annals of neurology.

[15]  M. Stacy,et al.  Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. , 2012, Parkinsonism & related disorders.

[16]  C. Gerfen,et al.  Modulation of striatal projection systems by dopamine. , 2011, Annual review of neuroscience.

[17]  F. Turkheimer,et al.  Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease , 2011, Neurology.

[18]  Y. Mizuno,et al.  Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[19]  Anatol C. Kreitzer,et al.  Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry , 2010, Nature.

[20]  J. Jankovic,et al.  Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study , 2010, Annals of neurology.

[21]  R. Hauser,et al.  Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[22]  M. Stacy,et al.  A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease , 2008, Neurology.

[23]  P. Tuite,et al.  Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005) , 2008, Annals of neurology.

[24]  F. Schmidt.  Meta-Analysis , 2008 .

[25]  E. Oztaş,et al.  Novel neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson's disease , 2006, Journal of the Neurological Sciences.

[26]  Miguel A Hernán,et al.  A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.

[27]  賢二 鈴木.  慢性副鼻腔炎に対するrandomized controlled study , 2002 .

[28]  K. Ikeda,et al.  Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease , 2002, Journal of neurochemistry.

[29]  G. E. Alexander,et al.  Functional architecture of basal ganglia circuits: neural substrates of parallel processing , 1990, Trends in Neurosciences.

[30]  G. Liang,et al.  Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson’s Disease: A Meta-analysis of Randomized Controlled Trials , 2014, Cell Biochemistry and Biophysics.

[31]  R. Zweig,et al.  Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. , 2010, Parkinsonism & related disorders.

[32]  Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. , 2009, Archives of neurology.